High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study
Lung cancer is one of leading causes of cancer death all over the world. Non-small cell lung cancer (NSCLC) is the most predominant subtype of lung cancer. Molecular targeting therapy has been shown great success in the treatment of advanced NSCLC. Thus, an easy, sensitive, and specific way of recog...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00491/full |
| _version_ | 1819149602077540352 |
|---|---|
| author | Yongqiang Li Jiajia Lv Shaogui Wan Shaogui Wan Junfang Xin Tiantian Xie Tao Li Wan Zhu Guosen Zhang Yunlong Wang Yitai Tang Ao Li Xiangqian Guo |
| author_facet | Yongqiang Li Jiajia Lv Shaogui Wan Shaogui Wan Junfang Xin Tiantian Xie Tao Li Wan Zhu Guosen Zhang Yunlong Wang Yitai Tang Ao Li Xiangqian Guo |
| author_sort | Yongqiang Li |
| collection | DOAJ |
| description | Lung cancer is one of leading causes of cancer death all over the world. Non-small cell lung cancer (NSCLC) is the most predominant subtype of lung cancer. Molecular targeting therapy has been shown great success in the treatment of advanced NSCLC. Thus, an easy, sensitive, and specific way of recognizing therapeutic gene targets would help to select effective treatments, to improve physical condition and increase patient survival. In this study, we recruited and followed up a female NSCLC patient, whose plasma ctDNAs (circulating tumor DNAs), blood cell DNAs, psDNAs (pleural effusion supernatant DNAs), and ppDNAs (pleural effusion pellet DNAs), were collected and analyzed over periodic time points by methods of next generation sequencing (NGS), droplet digital PCR (ddPCR), and Amplification Refractory Mutation System (ARMS). In addition, pleural effusion pellets were stained by IHC (immunohistochemistry). The investigation results showed that EGFR L858R mutation was recognized by methods of NGS, ddPCR, and ARMS, while EGFR T790M mutation was only identified by methods of NGS and ddPCR but not ARMS, indicating that ARMS as an auxiliary clinical diagnostic method, is less sensitive and less reliable than NGS and ddPCR. In summary, the non-invasive and sensitive way of collecting ctDNAs for NGS and/or ddPCR screenings offers patients new diagnosis and therapeutic options. |
| first_indexed | 2024-12-22T14:04:13Z |
| format | Article |
| id | doaj.art-c95b711588024d69b0953f3b1eff089c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T14:04:13Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c95b711588024d69b0953f3b1eff089c2022-12-21T18:23:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-10-01810.3389/fonc.2018.00491420848High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course StudyYongqiang Li0Jiajia Lv1Shaogui Wan2Shaogui Wan3Junfang Xin4Tiantian Xie5Tao Li6Wan Zhu7Guosen Zhang8Yunlong Wang9Yitai Tang10Ao Li11Xiangqian Guo12Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaLaboratory of Cancer Biomarkers and Liquid Biopsy, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaDepartment of Anesthesia, Stanford University, Stanford, CA, United StatesJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaHenan Bioengineering Research Center, Zhengdong New District, Zhengzhou, ChinaDepartment of Pathology, Stanford University, Stanford, CA, United StatesSchool of Information Science and Technology, Centers for Biomedical Engineering, University of Science and Technology of China, Hefei, ChinaJoint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, Department of Preventive Medicine, School of Basic Medical Sciences, Institute of Biomedical Informatics, Henan University, Kaifeng, ChinaLung cancer is one of leading causes of cancer death all over the world. Non-small cell lung cancer (NSCLC) is the most predominant subtype of lung cancer. Molecular targeting therapy has been shown great success in the treatment of advanced NSCLC. Thus, an easy, sensitive, and specific way of recognizing therapeutic gene targets would help to select effective treatments, to improve physical condition and increase patient survival. In this study, we recruited and followed up a female NSCLC patient, whose plasma ctDNAs (circulating tumor DNAs), blood cell DNAs, psDNAs (pleural effusion supernatant DNAs), and ppDNAs (pleural effusion pellet DNAs), were collected and analyzed over periodic time points by methods of next generation sequencing (NGS), droplet digital PCR (ddPCR), and Amplification Refractory Mutation System (ARMS). In addition, pleural effusion pellets were stained by IHC (immunohistochemistry). The investigation results showed that EGFR L858R mutation was recognized by methods of NGS, ddPCR, and ARMS, while EGFR T790M mutation was only identified by methods of NGS and ddPCR but not ARMS, indicating that ARMS as an auxiliary clinical diagnostic method, is less sensitive and less reliable than NGS and ddPCR. In summary, the non-invasive and sensitive way of collecting ctDNAs for NGS and/or ddPCR screenings offers patients new diagnosis and therapeutic options.https://www.frontiersin.org/article/10.3389/fonc.2018.00491/fulllung cancerctDNAsNGSnon-invasiveddPCR |
| spellingShingle | Yongqiang Li Jiajia Lv Shaogui Wan Shaogui Wan Junfang Xin Tiantian Xie Tao Li Wan Zhu Guosen Zhang Yunlong Wang Yitai Tang Ao Li Xiangqian Guo High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study Frontiers in Oncology lung cancer ctDNAs NGS non-invasive ddPCR |
| title | High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study |
| title_full | High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study |
| title_fullStr | High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study |
| title_full_unstemmed | High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study |
| title_short | High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study |
| title_sort | high sensitive and non invasive ctdnas sequencing facilitate clinical diagnosis and clinical guidance of non small cell lung cancer patient a time course study |
| topic | lung cancer ctDNAs NGS non-invasive ddPCR |
| url | https://www.frontiersin.org/article/10.3389/fonc.2018.00491/full |
| work_keys_str_mv | AT yongqiangli highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT jiajialv highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT shaoguiwan highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT shaoguiwan highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT junfangxin highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT tiantianxie highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT taoli highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT wanzhu highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT guosenzhang highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT yunlongwang highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT yitaitang highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT aoli highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy AT xiangqianguo highsensitiveandnoninvasivectdnassequencingfacilitateclinicaldiagnosisandclinicalguidanceofnonsmallcelllungcancerpatientatimecoursestudy |